Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis

BACKGROUND: An estimated 10–15% of non-small cell lung cancer (NSCLC) cases present with epidermal growth factor receptor mutation (EGFRm). While EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib have become first-line (1L) standard of care for these patients, limited chemotherapy use...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanderpoel, Julie, Emond, Bruno, Ghelerter, Isabelle, Milbers, Katherine, Lafeuille, Marie-Hélène, Lefebvre, Patrick, Ellis, Lorie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333158/
https://www.ncbi.nlm.nih.gov/pubmed/37074589
http://dx.doi.org/10.1007/s41669-023-00407-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333158/
https://www.ncbi.nlm.nih.gov/pubmed/37074589
http://dx.doi.org/10.1007/s41669-023-00407-0

Ejemplares similares